Castle Biosciences, Inc. (CSTL)
Company Info
Highlights
$468.60M
-$0.19
$347.08M
$298.06M
$37.27M
$15.45 - $35.84
$35.89
6.00%
3.86
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Castle Biosciences, Inc. (CSTL) returned -40.15% year-to-date (YTD) and -34.92% over the past 12 months.
CSTL
-40.15%
-19.65%
-47.60%
-34.92%
-11.07%
-16.13%
N/A
^GSPC (Benchmark)
0.52%
6.32%
-1.44%
12.25%
12.45%
14.20%
10.84%
Monthly Returns
The table below presents the monthly returns of CSTL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 6.08% | -23.31% | -7.66% | 0.15% | -20.45% | -40.15% | |||||||
| 2024 | 6.95% | -21.75% | 22.65% | -4.79% | 10.29% | -6.41% | 10.84% | 22.96% | -3.88% | 21.56% | -12.66% | -11.99% | 23.49% |
| 2023 | 15.04% | -7.02% | -9.77% | -0.40% | 7.95% | -43.84% | 22.81% | 18.28% | -15.25% | -7.52% | 27.98% | 7.95% | -8.33% |
| 2022 | 0.89% | 0.09% | 3.63% | -50.20% | -0.31% | -1.44% | 27.38% | 3.72% | -10.07% | -2.15% | -7.56% | -0.21% | -45.09% |
| 2021 | -0.48% | 13.84% | -10.02% | 0.83% | -13.18% | 22.36% | -4.75% | 9.85% | -13.33% | -6.24% | -33.71% | 3.73% | -36.16% |
| 2020 | -10.27% | -2.92% | -0.43% | 3.76% | 24.25% | -1.93% | 2.73% | 18.10% | 12.51% | -9.76% | 2.43% | 41.19% | 95.37% |
| 2019 | -8.18% | 42.09% | -35.21% | 30.13% | 14.40% | 27.63% | 60.61% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of CSTL is 18, meaning it’s performing worse than 82% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Castle Biosciences, Inc. (CSTL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Castle Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Castle Biosciences, Inc. was 88.02%, occurring on Jun 5, 2023. The portfolio has not yet recovered.
The current Castle Biosciences, Inc. drawdown is 83.61%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -88.02% | Feb 10, 2021 | 583 | Jun 5, 2023 | — | — | — |
| -43.62% | Sep 3, 2019 | 37 | Oct 23, 2019 | 16 | Nov 14, 2019 | 53 |
| -35.04% | Jan 7, 2020 | 48 | Mar 16, 2020 | 40 | May 12, 2020 | 88 |
| -21.13% | Jul 30, 2019 | 16 | Aug 20, 2019 | 4 | Aug 26, 2019 | 20 |
| -20.52% | Oct 12, 2020 | 33 | Nov 25, 2020 | 8 | Dec 8, 2020 | 41 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Castle Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Castle Biosciences, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -1,275.2%.
Valuation
The Valuation section provides an overview of how Castle Biosciences, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CSTL relative to other companies in the Diagnostics & Research industry. Currently, CSTL has a P/S ratio of 1.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CSTL in comparison with other companies in the Diagnostics & Research industry. Currently, CSTL has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |